abstract |
Disclosed are formulations and methods useful for reducing angiogenesis (new blood vessels in the cornea, retina, and / or choroid). According to the present invention, the formulation is present in a pharmaceutically acceptable form suitable for delivery to the eye at an approximately neutral pH and in an amount and duration sufficient to reduce ocular neovascularization. , Tetracycline or a derivative thereof including CMT that inhibits MMP activity. According to the present invention, the formulation is preferably a pharmaceutically acceptable formulation for topical ocular administration, ocular injection, or intraocular implant, and can be included in a liposome or sustained release capsule. [Selection figure] None |